Drug intelligence / Profile preview

CXCL2-neutralizing antibody

Development stage: Preclinical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intradermal, Intperitoneal, Intravenous, Intravitreal, Subcutaneous

Overview

A CXCL2-neutralizing antibody is a monoclonal antibody designed to bind and neutralize C-X-C motif chemokine ligand 2 (CXCL2), a chemokine involved in neutrophil recruitment, inflammation, and bone remodeling. In preclinical research, CXCL2 inhibition has been investigated for its therapeutic potential in age-related osteoporosis, where senescent osteocyte-derived CXCL2 drives bone loss by promoting osteoclastogenesis via FOXO3/SLC7A11-mediated ferroptosis. Additionally, CXCL2-neutralizing antibodies have been studied in models of bone healing, ischemic stroke, and inflammatory diseases to reduce neutrophil infiltration and tissue damage.

Other names: anti-C-X-C motif chemokine ligand 2 antibodyanti-CXCL2anti-CXCL-2anti-CXCL 2anti-CXCL2 antibodyanti-CXCL-2 antibodyanti-CXCL 2 antibodyanti-CXCL2 monoclonal antibodyanti-CXCL-2 monoclonal antibodyanti-CXCL 2 monoclonal antibodyCXCL2 neutralizing antibodyCXCL-2 neutralizing antibodyCXCL 2 neutralizing antibody

Targets

CXCL2 (C-X-C motif chemokine ligand 2)

Beyond the preview

Go deeper on CXCL2-neutralizing antibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CXCL2-neutralizing antibody.